Loading...
Geron Corporation
GERN•NASDAQ
Healthcare
Biotechnology
$1.14
$-0.01(-0.87%)
Geron Corporation (GERN) Financial Performance & Income Statement Overview
Review Geron Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
32386.92%
↑ 32386.92%
Operating Income Growth
10.42%
↑ 10.42%
Net Income Growth
5.19%
↑ 5.19%
Operating Cash Flow Growth
-30.33%
↓ 30.33%
Operating Margin
-115.49%
↓ 115.49%
Gross Margin
97.85%
↑ 97.85%
Net Profit Margin
-119.54%
↓ 119.54%
ROE
-48.46%
↓ 48.46%
ROIC
-26.89%
↓ 26.89%
Geron Corporation (GERN) Income Statement & Financial Overview
Review Geron Corporation's (GERN) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $47.54M | $28.27M | $882000.00 | $304000.00 |
| Cost of Revenue | $783000.00 | $62000.00 | $446000.00 | $275000.00 |
| Gross Profit | $46.75M | $28.21M | $436000.00 | $29000.00 |
| Gross Profit Ratio | $0.98 | $1.00 | $0.49 | $0.10 |
| R&D Expenses | $23.43M | $20.15M | $30.78M | $29.37M |
| SG&A Expenses | $43.37M | $35.88M | $38.99M | $26.79M |
| Operating Expenses | $66.80M | $56.49M | $69.77M | $56.16M |
| Total Costs & Expenses | $67.59M | $56.49M | $70.22M | $56.44M |
| Interest Income | $5.16M | $4.88M | $5.33M | $4.24M |
| Interest Expense | $8.71M | $3.05M | $3.32M | $3.43M |
| Depreciation & Amortization | $316000.00 | $201000.00 | $429000.00 | $275000.00 |
| EBITDA | -$16.33M | -$23.20M | -$63.63M | -$51.68M |
| EBITDA Ratio | -$0.34 | -$0.82 | -$72.15 | -$170.007 |
| Operating Income | -$20.05M | -$28.21M | -$69.33M | -$56.13M |
| Operating Income Ratio | -$0.42 | -$1.00 | -$78.61 | -$184.65 |
| Other Income/Expenses (Net) | -$5.30M | $1.77M | $1.95M | $744000.00 |
| Income Before Tax | -$25.35M | -$26.45M | -$67.38M | -$55.39M |
| Income Before Tax Ratio | -$0.53 | -$0.94 | -$76.40 | -$182.20 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $231724.00 |
| Net Income | -$25.35M | -$26.45M | -$67.38M | -$55.39M |
| Net Income Ratio | -$0.53 | -$0.94 | -$76.40 | -$182.20 |
| EPS | -$0.04 | -$0.04 | -$0.10 | -$0.09 |
| Diluted EPS | -$0.04 | -$0.04 | -$0.10 | -$0.09 |
| Weighted Avg Shares Outstanding | $646.03M | $662.16M | $653.90M | $603.49M |
| Weighted Avg Shares Outstanding (Diluted) | $646.03M | $662.16M | $653.90M | $603.49M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan